Moreover, the treatment with PD-L1–Gal-9 aEVs was observed to markedly attenuate T1D progression in a diabetic mouse model, accompanied by elevated levels of C-peptide and IL-10 expression. This evidence concerns the gene LGALS9 and type 1 diabetes mellitus.